On June 19, 2026 Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, and MOTE Therapeutics, a preclinical-stage biotech company developing a novel targeted LNP delivery platform and in vivo CAR-T therapies, reported their participation in the BIO International Convention 2026, taking place June 22–25 at the San Diego Convention Center. Both companies are members of Fapon Group. They will present their dual-targeting (CD19×BCMA), dual-platform (TCE + in vivo CAR-T) franchise designed to achieve deep and durable B-cell depletion through complementary therapeutic modalities, with both assets advancing toward human trials in the next six months.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The companies will exhibit at Booth 5435-2 in the Shanghai Pudong Pavilion, highlighting their complementary technology platforms, innovative pipeline across immuno-oncology and autoimmune diseases, and global partnership opportunities.
Two proprietary technology platforms serve as the engine behind this pipeline. Fapon Biopharma brings its proprietary VHH human-cynomolgus cross-binding T-cell engager platform, an innovative approach designed to overcome developability and therapeutic window constraints associated with traditional multi-specific immune cell engagers, featuring human-cynomolgus cross-reactivity, scalable GMP manufacturing with proven cell line development, and versatile molecular design. MOTE Therapeutics’ breakthrough mobilize targeted LNP (tLNP) platform is a next-generation in vivo gene delivery system that enables cell-specific targeted delivery and extrahepatic tissue distribution through a non-covalent, modular surface functionalization approach that requires no chemical conjugation.
The companies’ B-cell depletion franchise takes center stage at BIO 2026. This franchise features two differentiated programs targeting CD19 and BCMA, designed to deliver potent and sustained B-cell depletion: FPE024, a potential best-in-class CD19×BCMA×CD3 tri-specific T-cell engager for autoimmune indications, with IND filing targeted Q1 2027; and MTX001, a CD19×BCMA in vivo CAR-T program powered by the mobilize tLNP platform, with an investigator-initiated first-in-human study expected in Q4 2026.
In addition to the B-cell depletion franchise, the companies have built a robust pipeline spanning discovery, preclinical and clinical stages. Leading the clinical-stage pipeline is FP008, a global first-in-class PD1×IL10M fusion protein for immuno-oncology, currently in Phase I development with key readout anticipated in 2026. FP012 is a global first-in-class TL1A×IL10MM fusion protein for inflammatory bowel disease and other inflammatory and autoimmune indications. FPE021 is a potential best-in-class CDH17-targeting T-cell engager with a second co-stimulation signal for gastrointestinal tract cancers. Both FP012 and FPE021 are entering IND-enabling CMC/GLP toxicology in 2026.
Attendees interested in the science behind these programs can gain deeper insights during a dedicated company presentation, titled "Building a Dual-Targeting / Dual-Platform Franchise for B-Cell Immunotherapy" on Monday, June 22 at 4:30 PM PT in Room 3. The session will detail the technical design, development roadmap and commercial potential of the companies’ integrated dual-platform strategy for B-cell immunotherapy.
(Press release, Fapon Biopharma, JUN 19, 2026, View Source [SID1234668812])